Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
-
University of Alabama, Birmingham, Birmingham, Alabama, United States, 35294
Banner Alzheimer's Institute, Phoenix, Arizona, United States, 85006
Barrow Neurological Institute, Phoenix, Arizona, United States, 85013
Banner Sun Health Research Institute, Sun City, Arizona, United States, 85351
University of California, Irvine, Irvine, California, United States, 92697
University of California, San Diego, La Jolla, California, United States, 920371707
Long Beach VA Neuropsychiatric Research Program, Long Beach, California, United States, 90822
University of Southern California, Los Angeles, California, United States, 900335310
University of California, Los Angeles, Los Angeles, California, United States, 90095
VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States, 94304
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
55 Years to 90 Years
ALL
Yes
University of Southern California,
Michael W. Weiner, MD, STUDY_DIRECTOR, University of California, San Francisco
Paul Aisen, MD, PRINCIPAL_INVESTIGATOR, USC Alzheimer's Therapeutic Research Institute (ATRI)
Ronald Peterson, MD, PHD, PRINCIPAL_INVESTIGATOR, Mayo Clinic
2024-12